0001437749-22-018756.txt : 20220804 0001437749-22-018756.hdr.sgml : 20220804 20220804083042 ACCESSION NUMBER: 0001437749-22-018756 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220804 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220804 DATE AS OF CHANGE: 20220804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Avinger Inc CENTRAL INDEX KEY: 0001506928 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 208873453 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36817 FILM NUMBER: 221134869 BUSINESS ADDRESS: STREET 1: 400 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-363-2400 MAIL ADDRESS: STREET 1: 400 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 8-K 1 avgr20220803_8k.htm FORM 8-K avgr20220803_8k.htm
false 0001506928 0001506928 2022-08-04 2022-08-04
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 

 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):
 
August 4, 2022
 

 
Avinger, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-36817
 
20-8873453
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
400 Chesapeake Drive
Redwood City, California 94063
(Address of principal executive offices, including zip code)
 
(650) 241-7900
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
AVGR
The NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
 
Item 8.01. Other Events.
 
On August 4, 2022, Avinger, Inc. (the “Company”) issued a press release announcing the Company’s entry into a securities purchase agreement with a single institutional investor for the purchase and sale of 1,484,019 shares of its common stock at a purchase price of $1.752 per share (or pre-funded warrants in lieu thereof) and associated preferred investment options in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue and sell to the investor 1,369,864 shares of common stock at the same purchase price as in the registered direct offering (or pre-funded warrants in lieu thereof).
 
In addition, the Company has agreed to issue to the investor in the offerings unregistered series A preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock and series B preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock. The Series A preferred investment options have an exercise price of $1.502 per share, will be immediately exercisable, and will expire five and one-half years from the date of issuance and the Series B preferred investment options have an exercise price of $1.502 per share, will be immediately exercisable, and will expire two years from the date of issuance.
 
A copy of the Company’s press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.
 
Item 9.01. Financial Statements and Exhibits
 
(d) Exhibits.
 
Exhibit No.
 
Description
99.1
 
104
 
Cover Page Interactive Data File, formatted in Inline XBRL
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
AVINGER, INC.
 
     
Dated: August 4, 2022
/s/ Jeffrey M. Soinski
 
 
Jeffrey M. Soinski
 
 
Chief Executive Officer
 
 
 
EX-99.1 2 ex_406289.htm EXHIBIT 99.1 ex_406289.htm

Exhibit 99.1

 

Avinger Announces $5 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

 

Redwood City, Calif., August 4, 2022 - Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the sale and issuance of 1,484,019 shares of the Company’s common stock (or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. Concurrently with the registered direct offering, the Company entered into a definitive agreement with the investor in the registered direct offering for the sale and issuance of 1,369,864 shares of common stock (or pre-funded warrants in lieu thereof) in a private placement priced at-the-market under Nasdaq rules. The purchase price for one share of common stock (or pre-funded warrant in lieu thereof) and the associated preferred investment options is $1.752.

 

In addition, the Company has agreed to issue to the investor in the offerings unregistered series A preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock and series B preferred investment options to purchase up to 2,853,883 additional shares of the Company’s common stock (collectively, the “preferred investment options”). The Series A preferred investment options have an exercise price of $1.502 per share, will be immediately exercisable, and will expire five and one-half years from the date of issuance and the Series B preferred investment options have an exercise price of $1.502 per share, will be immediately exercisable, and will expire two years from the date of issuance.

 

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings.

 

The gross proceeds to Avinger from the offerings are expected to be approximately $5 million, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offerings primarily for working capital and general corporate purposes, which may include research and development of the Company’s Lumivascular platform products, preclinical and clinical trials and studies, regulatory submissions, expansion of sales and marketing organizations and efforts, intellectual property protection and enforcement and capital expenditures. The Company has not yet determined the amount of net proceeds to be used specifically for any particular purpose or the timing of these expenditures. The Company may use a portion of the net proceeds to acquire complementary products, technologies or businesses or to repay principal on debt; however, the Company currently has no binding agreements or commitments to complete any such transactions or to make any such principal repayments from the proceeds of the offerings, although the Company does look for such acquisition opportunities. Accordingly, the Company’s management will have significant discretion and flexibility in applying the net proceeds from the sale of these securities.

 

The closing of the offerings is expected to occur on or about August 8, 2022, subject to the satisfaction of customary closing conditions.

 

The shares of common stock, pre-funded warrants and shares of common stock underlying the pre-funded warrants (but excluding the shares of common stock and pre-funded warrants to be issued in the private placement and the preferred investment options and the shares of common stock underlying the preferred investment options) being offered by the Company in the registered direct offering are being offered pursuant to a "shelf" registration statement on Form S-3 (File No. 333-263922) previously filed with the Securities and Exchange Commission (the "SEC") on March 29, 2022, and declared effective by the SEC on April 7, 2022. The offering of the common stock and pre-funded warrants in the registered direct offering is made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the securities being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov. and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

 

 

 

The securities offered pursuant to the private placement, as well as the preferred investment options being issued to investors in the registered directed offering and the shares of common stock issuable thereunder, are being offered in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, those securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

 

Under a registration rights agreement with the investors, the Company has agreed to file a registration statement with the SEC covering the resale of the securities to be issued in the private placement and the shares of common stock underlying the preferred investment options to be issued in both offerings.

 

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

 

About Avinger, Inc.

Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and TigereyeTM family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

 

Follow Avinger on Twitter and Facebook.

 

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the satisfaction of the customary conditions to the closing of the registered direct offering and the private placement, the consummation of the offerings; our intended use of proceeds from the offerings, our future performance, patient and physician benefits of our products, the impacts of our products on the treatment of vascular disease, improvement of capacity constraints at hospitals, expansion of our catheter solutions, our ability to successfully develop new products, including products relating to the treatment of CAD, the timing of the development of new products, the impact of products developed for the treatment of CAD on our business and results of operations, and the timing of submission and approval of 510(k) applications for two new catheters in our peripheral product portfolio. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market and other conditions; our dependency on a limited number of products; the resource requirements related to Pantheris, Tigereye and our Lightbox imaging console; the outcome of clinical trial results; the adoption of our products by physicians; our ability obtain regulatory approvals for our products; as well as the other risks described in the section entitled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2021 and our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2022. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Avinger disclaims any obligation to update these forward- looking statements, except as required by law.

 

 

 

Investor Contact:

 

ir@avinger.com

 

Matt Kreps

Darrow Associates Investor Relations

(214) 597-8200

mkreps@darrowir.com

 

Public Relations Contact:

Phil Preuss

Chief Marketing Officer

Avinger, Inc.

(650) 241-7942

pr@avinger.com

 

 

 
EX-101.SCH 3 avgr-20220804.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 avgr-20220804_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 avgr-20220804_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 avgr-20220804_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document And Entity Information
Aug. 04, 2022
Document Information [Line Items]  
Entity, Registrant Name Avinger, Inc.
Document, Type 8-K
Document, Period End Date Aug. 04, 2022
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-36817
Entity, Tax Identification Number 20-8873453
Entity, Address, Address Line One 400 Chesapeake Drive
Entity, Address, City or Town Redwood City
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 94063
City Area Code 650
Local Phone Number 241-7900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol AVGR
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001506928
XML 8 avgr20220803_8k_htm.xml IDEA: XBRL DOCUMENT 0001506928 2022-08-04 2022-08-04 false 0001506928 8-K 2022-08-04 Avinger, Inc. DE 001-36817 20-8873453 400 Chesapeake Drive Redwood City CA 94063 650 241-7900 false false false false Common Stock AVGR NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.avgr.com/20220804/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports avgr20220803_8k.htm avgr-20220804.xsd avgr-20220804_def.xml avgr-20220804_lab.xml avgr-20220804_pre.xml ex_406289.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "avgr20220803_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "avgr-20220804_def.xml" ] }, "inline": { "local": [ "avgr20220803_8k.htm" ] }, "labelLink": { "local": [ "avgr-20220804_lab.xml" ] }, "presentationLink": { "local": [ "avgr-20220804_pre.xml" ] }, "schema": { "local": [ "avgr-20220804.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "avgr", "nsuri": "http://www.avgr.com/20220804", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "avgr20220803_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.avgr.com/20220804/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "avgr20220803_8k.htm", "contextRef": "d20228K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.avgr.com/20220804/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001437749-22-018756-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-22-018756-xbrl.zip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end